ライフサイエンスコーパス: avian sarcoma

1 The study of the interactions of subgroup A avian sarcoma and leucosis viruses [ASLV(A)] with the TV

2 ystem, a well established model for studying avian sarcoma and leukemia oncogenes, we probed the tran

3 In avian sarcoma and leukemia viruses (ASLV), PR forms the

4 in Rous sarcoma virus, the prototype of the avian sarcoma and leukemia viruses.

5 better elucidated the viral entry process of avian sarcoma and leukosis virus (ASLV) and human immuno

6 The retrovirus avian sarcoma and leukosis virus (ASLV) enters cells via

7 imaged fusion between single virions bearing avian sarcoma and leukosis virus (ASLV) envelope glycopr

8 The entry process of the avian sarcoma and leukosis virus (ASLV) family of retrov

9 In a previous study, we found avian sarcoma and leukosis virus (ASLV) gag genes in 19

10 distribution of avian retroviruses, we found avian sarcoma and leukosis virus (ASLV) gag genes in 26

11 hic effect (CPE) seen with some subgroups of avian sarcoma and leukosis virus (ASLV) is associated wi

12 f Tva-expressing avian or mammalian cells by avian sarcoma and leukosis virus (ASLV) or EnvA-pseudoty

13 "priming" model for entry of the retrovirus avian sarcoma and leukosis virus (ASLV) predicts that up

14 cterization of the defect associated with an avian sarcoma and leukosis virus (ASLV) receptor resista

15 Binding of avian sarcoma and leukosis virus (ASLV) to its cognate r

16 ective MLV vector and LTR expression from an avian sarcoma and leukosis virus (ASLV) vector.

17 el entry mechanism has been proposed for the avian sarcoma and leukosis virus (ASLV), whereby interac

18 e efficiency of acid-dependent fusion of the avian sarcoma and leukosis virus (ASLV), with endosomes.

19 of Tva, the cellular receptor for subgroup A avian sarcoma and leukosis virus (ASLV-A), in viral entr

20 ration that Tva, the receptor for subgroup A avian sarcoma and leukosis virus (ASLV-A), induces confo

21 d to express the TVA receptor for subgroup A avian sarcoma and leukosis virus (ASLV-A), the five cell

22 it, of the Env glycoprotein of the subtype A avian sarcoma and leukosis virus (ASLV-A).

23 Tva is the cellular receptor for subgroup A avian sarcoma and leukosis virus (ASLV-A).

24 Tva is the cellular receptor for subgroup A avian sarcoma and leukosis virus (ASLV-A).

25 rly steps of retroviral replication by using avian sarcoma and leukosis virus as a model retrovirus.

26 The avian sarcoma and leukosis virus envelope glycoproteins,

27 tor of a model retrovirus, subgroup A of the Avian Sarcoma and Leukosis Virus genus (ASLV-A), was stu

28 The fusion protein of avian sarcoma and leukosis virus is likely to fold into

29 Furthermore, later steps of avian sarcoma and leukosis virus reverse transcription w

30 Avian sarcoma and leukosis virus subgroup A (ASLV-A) ent

31 ding to the two heptad repeat domains of the avian sarcoma and leukosis virus subgroup A (ASLV-A) TM

32 tages at which the envelope protein (Env) of avian sarcoma and leukosis virus subgroup A folds into a

33 Avian sarcoma and leukosis viruses (ASLV) are unusual am

34 Receptor specificity in avian sarcoma and leukosis viruses (ASLV) maps to the ce

35 gene conferring susceptibility to subgroup A avian sarcoma and leukosis viruses (ASLV-A) was recently

36 The TVB receptor for subgroup B, D, and E avian sarcoma and leukosis viruses (ASLVs) is a tumor ne

37 The receptor for the subgroup A avian sarcoma and leukosis viruses [ASLV(A)] is the cell

38 ified and cloned the receptor for subgroup C avian sarcoma and leukosis viruses [ASLV(C)], i.e., Tvc,

39 f the extracellular region of the subgroup A avian sarcoma and leukosis viruses envelope glycoprotein

40 HTLV-1, HIV-1, murine leukaemia virus (MLV), avian sarcoma leucosis virus (ASLV) and prototype foamy

41 ion of the mature carboxyl terminus of CA in avian sarcoma/leukemia virus is the result of a sequence

42 , named CA2 and CA3, that can be detected in avian sarcoma/leukemia virus.

43 The budding of avian sarcoma leukosis virus and HIV-1 Gag virus-like pa

44 the Vps4 protein does not associate with the avian sarcoma leukosis virus or the HIV-1 budding comple

45 e glycoprotein and its specific receptor for avian sarcoma leukosis virus subgroup A or B) system all

46 from those of Moloney murine leukemia virus, avian sarcoma leukosis virus, and foamy virus.

47 on proteins of human immunodeficiency virus, avian sarcoma leukosis virus, and influenza virus was in

48 ndogenous avian virus (EAV) family or to the avian sarcoma-leukosis virus (ALV)-related subgroup E en

49 al substrate sequence of 5'-ACGACAACA-3' for avian sarcoma-leukosis virus (ASLV) and 5'-AACA(A/C)AGCA

50 zed the placement of sites of integration of avian sarcoma-leukosis virus (ASLV) and human immunodefi

51 On the other hand, integration of avian sarcoma-leukosis virus (ASLV) shows little prefere

52 te that retroviral infection mediated by the avian sarcoma-leukosis virus (ASLV-A) envelope glycoprot

53 n leukosis virus RCAS (replication-competent avian sarcoma-leukosis virus LTR splice acceptor)-mediat

54 ratory described selection from a subgroup B avian sarcoma-leukosis virus of an extended-host-range v

55 deficiency virus, murine leukemia virus, and avian sarcoma-leukosis virus, and found that a statistic

56 to test this model for the avian retrovirus avian sarcoma/leukosis virus (ASLV) and the filovirus eb

57 envelope glycoprotein (Env) of the oncovirus avian sarcoma/leukosis virus (ASLV) contains an internal

58 The fusion peptide of the avian sarcoma/leukosis virus (ASLV) envelope protein (En

59 The avian sarcoma/leukosis virus (ASLV) is activated for fus

60 Some retroviruses, such as avian sarcoma/leukosis virus (ASLV), employ a two-step m

61 ous attempts to extend the host range of the avian sarcoma/leukosis virus (ASLV)-based RCASBP vectors

62 integration reaction was found for HIV-1 and avian sarcoma/leukosis virus but not murine leukemia vir

63 ed in vivo HIV-1, murine leukemia virus, and avian sarcoma/leukosis virus integrations.

64 wed that the envelope glycoprotein (EnvA) of avian sarcoma/leukosis virus subtype A (ASLV-A) binds to

65 flanking the internal fusion peptide of the avian sarcoma/leukosis virus subtype A (ASLV-A) Env (Env

66 The receptor for avian sarcoma/leukosis virus subtype A (ASLV-A), Tva, is

67 m amphotropic murine leukemia virus (A-MLV), avian sarcoma/leukosis virus type A (ASLV-A), and influe

68 P-M2C is a retroviral vector derived from an avian sarcoma/leukosis virus which has been modified so

69 characterized two new replication-competent avian sarcoma/leukosis virus-based retroviral vectors wi

70 ive beta-catenin using replication competent avian sarcoma (RCAS) virus.

71 We have used the replication-competent avian sarcoma retrovirus to deliver exogenous genes to r

72 (MYC) through the direct activation of v-src avian sarcoma viral oncogene homolog (SRC) and suppressi

73 etected independently of catalysis with both avian sarcoma virus (ASV) and human immunodeficiency vir

74 es of the core domain of integrase (IN) from avian sarcoma virus (ASV) and its active-site derivative

75 The direct-repeat elements (dr1) of avian sarcoma virus (ASV) and leukosis virus have the pr

76 human immunodeficiency virus type 1 (HIV-1), avian sarcoma virus (ASV) and their close orthologs from

77 Recent studies have demonstrated that avian sarcoma virus (ASV) can transduce cycle-arrested c

78 We have described a reconstituted avian sarcoma virus (ASV) concerted DNA integration syst

79 Using a model system in which avian sarcoma virus (ASV) DNA is epigenetically represse

80 of E3 ubiquitin ligases bind the L domain in avian sarcoma virus (ASV) Gag and facilitate viral parti

81 Reverse transcription in avian sarcoma virus (ASV) initiates from the 3' end of a

82 nt of HIV-1, simian sarcoma virus (SIV), and avian sarcoma virus (ASV) INs predicted which of these r

83 in Daxx was identified as an interactor with avian sarcoma virus (ASV) integrase (IN) in a yeast two-

84 determined the size and shape of full-length avian sarcoma virus (ASV) integrase (IN) monomers and di

85 (aa) in the C-terminal region of the 286-aa avian sarcoma virus (ASV) integrase (IN) protein has bee

86 In contrast, integration by avian sarcoma virus (ASV) integrase was more efficient a

87 Here, we report the mapping of 226 avian sarcoma virus (ASV) integration sites in the human

88 The process by which the avian sarcoma virus (ASV) preintegration complex gains a

89 s comparable to one previously described for avian sarcoma virus (ASV) that was stimulated by the pre

90 the integrase protein of an oncoretrovirus, avian sarcoma virus (ASV), suggesting an active import m

91 netic repression and silencing of integrated avian sarcoma virus (ASV)-based vector DNAs in human HeL

92 same requirement for the simple retrovirus, avian sarcoma virus (ASV).

93 The avian sarcoma virus 16 (ASV 16) is a retrovirus that ind

94 The retroviral oncogene p3k (v-p3k) of avian sarcoma virus 16 (ASV16) codes for the catalytic s

95 ne is a cell-derived insert in the genome of avian sarcoma virus 31 (ASV 31) and functions as the onc

96 Despite sequence differences between avian sarcoma virus and HIV-1 IN and their recognition s

97 hly preferred in vitro integration sites for avian sarcoma virus and human immunodeficiency virus-1 i

98 tion as seen in the integrase core domain of avian sarcoma virus as well as human immunodeficiency vi

99 of integration catalyzed by HIV-1 to that of avian sarcoma virus by analyzing the effect of defined m

100 f chicken embryos with replication-competent avian sarcoma virus expressing either FgfR2(C278F), a re

101 es have indicated that in the context of the avian sarcoma virus genome, precise deletion of both ASV

102 m permanganate modification to show that the avian sarcoma virus IN catalytic domain is able to disto

103 he metal preference for in vitro activity of avian sarcoma virus IN is Mn2+ > Mg2+ and that a single

104 at the putative dimer-dimer interface of the avian sarcoma virus IN with its analogue, loop188-194, f

105 ar strategy, the unique amino acids found in avian sarcoma virus IN, rather than HIV-1 or Mason-Pfize

106 domain, or the isolated catalytic domain of avian sarcoma virus IN.

107 phic studies of the catalytic core domain of avian sarcoma virus integrase (ASV IN) have provided the

108 itor complex of the catalytic core domain of avian sarcoma virus integrase (ASV IN) were solved at 1.

109 of human immunodeficiency virus-1 integrase, avian sarcoma virus integrase, and bacteriophage Mu tran

110 Using the avian sarcoma virus integrase, we demonstrate that the e

111 of host sequences, as is characteristic for avian sarcoma virus integration.

112 the selection and characterization of novel avian sarcoma virus mutants.

113 in human (HeLa) cells, mediated by either an avian sarcoma virus or a human immune deficiency virus t

114 lected were substrates of HIV protease or of avian sarcoma virus protease, both of which have been re

115 t reduction in the total amount of HIV-1 and avian sarcoma virus retroviral vector DNA that is joined

116 of human immunodeficiency virus (HIV) RT or avian sarcoma virus RT.

117 The avian sarcoma virus UR2 codes for an oncogenic Gag-Ros f

118 n embryo fibroblasts (CEF) infected with the avian sarcoma virus UR2, encoding the oncogenic receptor

119 Simple retroviruses, such as avian sarcoma virus, do not encode regulatory proteins t

120 d HeLa cell populations that harbored silent avian sarcoma virus-based green fluorescent protein (GFP

121 ICP34.5 of herpes simplex virus and NL-S of avian sarcoma virus.